TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00390130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel (DPTaP+Hib)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar (conjugated pneumococcal vaccine)
Study: NCT04161014

Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib 150 MG [Ofev]
Description: Nintedanib 150mg twice daily for 3 years
Study: NCT04646486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video debriefing
Description: Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
Study: NCT03564301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
Study: NCT00071097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: 800mg TMC114/100mg rtv once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: 400mg TMC114/100mg rtv both twice daily
Study: NCT00896155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
Study: NCT02971943

Intervention type: PROCEDURE
Group type: OTHER
Intervention: internal fixation for ankle fractures
Description: The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373 + leucovorin
Description: NUC-3373 + leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373 + leucovorin
Description: NUC-3373 + leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373 + leucovorin
Description: NUC-3373 + leucovorin
Study: NCT00896155

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
Study: NCT03501836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Rhythm Handheld 8-lead ECG Device
Description: We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future.
Study: NCT01775865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 4 weeks of daily salsalate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for salsalate)
Description: 4 week of daily placebo
Study: NCT04368611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: start with fundus
Description: fundus first dissection then complete cholecystectomy as usual

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: calot first dissection
Description: start dissection by calot approach
Study: NCT02702713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy BEF
Description: Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Egg BEF
Description: Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373
Description: NUC-3373
Study: NCT02702713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bakery BEF
Description: Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
Study: NCT01170702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% Ropivacaine
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ropivacaine
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
Study: NCT04615546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Continuous Glucose Monitor (CGM)
Description: Participants will wear CGM
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFOX
Description: NUC-3373 + oxaliplatin
Study: NCT02702713

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bakery placebo
Description: Bakery placebo: Biscuits without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bakery placebo
Description: Bakery placebo: Biscuits without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bakery placebo
Description: Bakery placebo: Biscuits without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy placebo
Description: Dairy placebo: Milkshake powder without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy placebo
Description: Dairy placebo: Milkshake powder without enrichment
Study: NCT04615546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Cardea Solo monitoring
Description: Participants will wear a Cardea Solo patch during blinded CGM use
Study: NCT03376516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: von Willebrand factor / Factor VIII (plasma derived)
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFOX
Description: NUC-3373 + oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFOX + VEGF pathway inhibitor
Description: NUC-3373 + oxaliplatin + bevacizumab
Study: NCT03690908

Intervention type: OTHER
Intervention: no intervention (descriptive study)
Description: no intervention (descriptive study)

Intervention type: OTHER
Intervention: no intervention (descriptive study)
Description: no intervention (descriptive study)
Study: NCT03206372

Intervention type: OTHER
Intervention: Case group
Description: Questionnaire to be completed, blood sample and possibly echo-doppler
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFOX + VEGF pathway inhibitor
Description: NUC-3373 + oxaliplatin + bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFOX + EGFR inhibitor
Description: NUC-3373 + oxaliplatin + cetuximab/panitumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFIRI
Description: NUC-3373 + irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFIRI
Description: NUC-3373 + irinotecan
Study: NCT03206372

Intervention type: OTHER
Intervention: Control group
Description: Questionnaire to be completed, blood sample and possibly echo-doppler
Study: NCT01482858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrolith
Description: Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
Study: NCT00370292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - Before Protocol Amendment
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - After Protocol Amendment
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
Study: NCT03428958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFIRI + VEGF pathway inhibitor
Description: NUC-3373 + irinotecan + bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFIRI + VEGF pathway inhibitor
Description: NUC-3373 + irinotecan + bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUFIRI + EGFR inhibitor
Description: NUC-3373 + irinotecan + cetuximab/panitumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373 + bevacizumab
Description: NUC-3373 + bevacizumab
Study: NCT04484753

Intervention type: OTHER
Group type: OTHER
Intervention: Home Exercise Sheet
Description: Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.

Intervention type: OTHER
Group type: OTHER
Intervention: Ipelvis mobile application
Description: Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise sheet + Pelvic Physiotherapy
Description: Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipelvis mobile application + Pelvic Physiotherapy
Description: Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
Study: NCT00071097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: 400mg TMC114/100mg rtv once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: 600mg TMC114/100mg rtv twice daily
Study: NCT02224924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABPI
Description: If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug
Description: If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
Study: NCT02028845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation with loop guidewire
Description: Selective biliary cannulation during endoscopic retrograde cholangiopancreatography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation with straight guidewire
Description: Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
Study: NCT00799396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300 mg on first day, then 75 mg per day for the next 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Single dose of 324 mg on the last day of clopidogrel treatment
Study: NCT01556724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% or 0.2% ropivacaine nerve blocks
Description: Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% or 0.2% ropivacaine nerve blocks
Description: Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
Study: NCT00300131

Intervention type: DEVICE
Intervention: Bioabsorbable Everolimus Eluting Coronary Stent
Description: Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
Study: NCT01682577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg tablets of PT Dexa Medica
Description: Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril 4 mg tablets of Servier
Description: Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study: NCT04141553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem Injection
Description: Randomization to one of to active comparator groups
Study: NCT02702713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy placebo
Description: Dairy placebo: Milkshake powder without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg placebo
Description: Egg placebo: Frozen pancakes without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Egg placebo
Description: Egg placebo: Frozen pancakes without enrichment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Egg placebo
Description: Egg placebo: Frozen pancakes without enrichment
Study: NCT05565339

Intervention type: DEVICE
Intervention: PMEIs
Description: To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated.

Intervention type: DEVICE
Intervention: PMEIs
Description: To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated.

Intervention type: DEVICE
Intervention: PMEIs
Description: To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated.
Study: NCT01333280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Trouble in Recovery
Description: DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Receive usual treatment at the programs
Study: NCT00728442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCODOC LOGICIEL
Description: Introduction of a computer-based decision support system in the medical decision process
Study: NCT02713906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-Ray Knee Guide group
Study: NCT02780440

Intervention type: BEHAVIORAL
Intervention: Traditional Home Based Exercise Program
Description: Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.

Intervention type: BEHAVIORAL
Intervention: Unimanual Home Based Mirror Therapy Program
Description: The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.

Intervention type: BEHAVIORAL
Intervention: Bimanual Home Based Mirror Therapy Program
Description: The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
Study: NCT01827124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Study: NCT02350634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Description: Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie \[mCi\]) of 18F-AV-1451.
Study: NCT05166954

Intervention type: PROCEDURE
Intervention: LSG
Description: Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
Study: NCT04099277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3435151
Description: Administered IV
Study: NCT05166954

Intervention type: PROCEDURE
Intervention: RYGB
Description: Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
Study: NCT02487277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Study: NCT04099277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3435151
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3435151
Description: Administered IV
Study: NCT02487277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel